Cargando…
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
PURPOSE: To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort. PATIENTS AND METHODS: A prospective...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755368/ https://www.ncbi.nlm.nih.gov/pubmed/33376379 http://dx.doi.org/10.2147/JIR.S282249 |
_version_ | 1783626340464852992 |
---|---|
author | Zhang, Le Chen, Fangfang Geng, Shikai Wang, Xiaodong Gu, Liyang Lang, Yitian Li, Ting Ye, Shuang |
author_facet | Zhang, Le Chen, Fangfang Geng, Shikai Wang, Xiaodong Gu, Liyang Lang, Yitian Li, Ting Ye, Shuang |
author_sort | Zhang, Le |
collection | PubMed |
description | PURPOSE: To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort. PATIENTS AND METHODS: A prospective RA cohort (n=549) was screened with eligible patients who had inadequate response (disease activity score in 28 joints using erythrocyte sedimentation rate, DAS28-ESR>3.2) to initial MTX monotherapy and subsequently received either MTX+HCQ or MTX+LEF. Propensity score matching (PSM) was applied to adjust the possible baseline confounders between two groups. The primary outcome was the proportion of patients achieving first remission (DAS28-ESR<2.6) during follow-up by log rank test. Secondary outcomes were changes of DAS28, glucocorticoids (GCs) exposure, safety, cost-effectiveness, sustained remission, and low disease activity (LDA) rate after 24-month follow-up. RESULTS: Overall, 222 eligible patients were subjected to the aforementioned two treatment protocols (MTX+HCQ, n=102; MTX+LEF, n=120). After PSM adjustment, 97 patients in each group were analyzed. A higher remission rate was observed in the MTX+HCQ group than in the MTX+LEF group (70.1% vs 56.7%, P=0.048). The median time to remission was 11 and 16 months in the two groups, respectively. At the endpoint, more patients achieved remission (46.8% vs 32.5%, P=0.063) and maintained sustained LDA in the HCQ group (53.2% vs 38.6%, P=0.062) and also more patients withdrew GCs in this group (32% vs 16.7%, P=0.053) than those in the LEF group. Safety profiles were non-alarming, with no significant difference between the two groups. The incremental cost-effectiveness ratio yielded by MTX+HCQ over MTX+LEF was $1,111.8 per quality-adjusted life-year (QALY), within the cost-effective threshold set as the per capita gross domestic product (GDP) of China. CONCLUSION: The MTX+HCQ combination was seemingly superior to MTX+LEF in a real-world cohort of Chinese RA patients with inadequate response to methotrexate monotherapy in respect of the efficacy and cost-effectiveness. |
format | Online Article Text |
id | pubmed-7755368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77553682020-12-28 Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World Zhang, Le Chen, Fangfang Geng, Shikai Wang, Xiaodong Gu, Liyang Lang, Yitian Li, Ting Ye, Shuang J Inflamm Res Original Research PURPOSE: To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort. PATIENTS AND METHODS: A prospective RA cohort (n=549) was screened with eligible patients who had inadequate response (disease activity score in 28 joints using erythrocyte sedimentation rate, DAS28-ESR>3.2) to initial MTX monotherapy and subsequently received either MTX+HCQ or MTX+LEF. Propensity score matching (PSM) was applied to adjust the possible baseline confounders between two groups. The primary outcome was the proportion of patients achieving first remission (DAS28-ESR<2.6) during follow-up by log rank test. Secondary outcomes were changes of DAS28, glucocorticoids (GCs) exposure, safety, cost-effectiveness, sustained remission, and low disease activity (LDA) rate after 24-month follow-up. RESULTS: Overall, 222 eligible patients were subjected to the aforementioned two treatment protocols (MTX+HCQ, n=102; MTX+LEF, n=120). After PSM adjustment, 97 patients in each group were analyzed. A higher remission rate was observed in the MTX+HCQ group than in the MTX+LEF group (70.1% vs 56.7%, P=0.048). The median time to remission was 11 and 16 months in the two groups, respectively. At the endpoint, more patients achieved remission (46.8% vs 32.5%, P=0.063) and maintained sustained LDA in the HCQ group (53.2% vs 38.6%, P=0.062) and also more patients withdrew GCs in this group (32% vs 16.7%, P=0.053) than those in the LEF group. Safety profiles were non-alarming, with no significant difference between the two groups. The incremental cost-effectiveness ratio yielded by MTX+HCQ over MTX+LEF was $1,111.8 per quality-adjusted life-year (QALY), within the cost-effective threshold set as the per capita gross domestic product (GDP) of China. CONCLUSION: The MTX+HCQ combination was seemingly superior to MTX+LEF in a real-world cohort of Chinese RA patients with inadequate response to methotrexate monotherapy in respect of the efficacy and cost-effectiveness. Dove 2020-12-18 /pmc/articles/PMC7755368/ /pubmed/33376379 http://dx.doi.org/10.2147/JIR.S282249 Text en © 2020 Zhang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zhang, Le Chen, Fangfang Geng, Shikai Wang, Xiaodong Gu, Liyang Lang, Yitian Li, Ting Ye, Shuang Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title | Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title_full | Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title_fullStr | Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title_full_unstemmed | Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title_short | Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World |
title_sort | methotrexate (mtx) plus hydroxychloroquine versus mtx plus leflunomide in patients with mtx-resistant active rheumatoid arthritis: a 2-year cohort study in real world |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755368/ https://www.ncbi.nlm.nih.gov/pubmed/33376379 http://dx.doi.org/10.2147/JIR.S282249 |
work_keys_str_mv | AT zhangle methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT chenfangfang methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT gengshikai methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT wangxiaodong methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT guliyang methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT langyitian methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT liting methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld AT yeshuang methotrexatemtxplushydroxychloroquineversusmtxplusleflunomideinpatientswithmtxresistantactiverheumatoidarthritisa2yearcohortstudyinrealworld |